Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

He also teaches health science and research writing at George Washington University's School of Medical and Health Sciences.

In July, the Summer Law and Trial Institute (SLTI) welcomed 24 high school students from across the state of Ohio both to Athens and to the practice of law. OHIO's faculty and staff, across various ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

A team from Kumamoto University has uncovered a new mechanism that could revolutionize infertility care by promoting embryo ...

Philip Morris said it expects to record a loss on the sale of its inhaled-therapeutics unit to Molex Asia Holdings as it retools its pharmaceutical business. The head of the social-media app said ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...